A researcher in Germany has been banned from seeking money from the largest independent research funder in the country for five years after an investigation by her former employer found her guilty of misconduct.
A researcher in South Korea has retracted a 2015 paper after telling the journal he falsified the institutional approval required to conduct the animal experiments.
In the article, the author explicitly says that the Animal Experiment Review Board of a university based in Seoul, South Korea approved the experiments, but according to the journal, “the author did not receive an approval by the board and he used a false approval number.”
The authors of a 2014 study about asthma in Norwegian athletes have retracted it after realizing they hadn’t obtained proper approval from an ethical committee.
The study’s first and corresponding author of the study in the British Journal of Sports Medicine — Julie Stang from the Norwegian School of Sports Sciences in Oslo — told us the authors had struggled to obtain ethical approval for the research, but believed the issue had been resolved.
However, earlier this year, a member of an ethical committee wrote an article in the Norwegian press about his concerns regarding the study, which tested the effects of three drugs on top athletes’ breathing. In it, he said the Regional Committees for medical and health professional research ethics (REC) had not approved the study, as members were concerned the presumably healthy athletes were being exposed to drugs used to treat asthma, which could enhance their performance.
Stang has denied that the study had anything to do with boosting athletic performance.
A California court ruled that fitness empire CrossFit can proceed to trial with its lawsuit against a competitor, alleging it published falsified data that hurt the company’s reputation, according to recently released court documents.
The case pits the popular for-profit CrossFit brand against the non-profit National Strength and Conditioning Association (NSCA), which published the 2013 study in question.
The study appeared in the Journal of Strength & Conditioning Research, published by CrossFit competitor NSCA, which also promotes fitness programs. CrossFit claims the results in the paper cost it revenues from people paying for seminars at CrossFit, Inc. affiliate gyms.
A bone researcher based in Japan with 10 retractions under his belt has retracted two more papers for similar reasons — problems with the underlying data, and including co-authors who didn’t participate in the project.
In both notices, Yoshihiro Sato is pegged as responsible for the content of the papers. The newly retracted research covers a long timespan — one paper was published in 2000, the other in 2013.
Federal judges in Ohio have dismissed two lawsuits claiming that university researchers used false results to secure more than $250 million in federal grants.
Both lawsuits, which objected to a study examining the effects of CrossFit-based training, were filed by Mitchell Potterf, the owner of a gym affiliated with CrossFit in Columbus, Ohio. Potterf took issue with a 2013 study by researchers at Ohio State University (OSU) that was conducted at his gym.
A rheumatology journal has retracted a paper about treating knee pain after an institutional investigation found a mistake in the statistical process.
Over several months, the authors proposed a series of corrections to the 2014 study. However, the journal Annals of the Rheumatic Diseases (ARD) decided that there were “unresolved concerns” about the reliability of the data, and decided to retract the paper entirely, despite the authors’ objections.
The corresponding author asked the Journal of Pediatric Orthopaedics to retract an article that found popular pain medicines can curb growth in rats, in light of an unresolved authorship dispute.
The article, “Nonsteroidal Anti-Inflammatory Drugs Cause Inhibition of the Growth Plate in Cultured Rat Metatarsal Bones,” details preliminary results that indicate nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce growth in rat bones in a dose-dependent manner, suggesting caution in treating chronic inflammatory diseases in children. The editor told us the paper was “highly rated” by reviewers and the results were “never in question,” but the senior author asked to pull the paper after failing to resolve a dispute with a researcher who asked to be added as an author.